Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.36 |
| ▸ | LCK | P06239 | 3/20 | 0.36 |
| ▸ | TEK | Q02763 | 2/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 7/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 2/20 | 0.30 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
| ▸ | ABL2 | P42684 | 2/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | LTK | P29376 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18052582 | 0.94 | LCK (0.38) | GSK3BDYRK1ASRCLCKTEK | |
| SCHEMBL18052578 | 0.90 | SRC (0.38) | SRCLCKTEKBRD9JAK2 | |
| SCHEMBL18052586 | 0.88 | BRD9 (0.38) | SRCLCKTEKBRD9HCAR1 | |
| SCHEMBL16726643 | 0.85 | GSK3B (0.40) | GSK3BDYRK1ASRCLCKTEK | |
| SCHEMBL16610905 | 0.84 | CA12 (0.39) | GSK3BDYRK1ASRCLCKTEK | |
| SCHEMBL16611042 | 0.80 | GSK3B (0.36) | GSK3BDYRK1ASRCLCKTEK | |
| SCHEMBL18052592 | 0.80 | BRD9 (0.30) | BRD9 | |
| SCHEMBL16623549 | 0.79 | LCK (0.38) | GSK3BDYRK1ASRCLCKTEK | |
| SCHEMBL18052580 | 0.78 | CREBBP (0.38) | JAK2JAK1 | |
| SCHEMBL16610867 | 0.78 | CA12 (0.38) | SRCLCKTEKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | GSK3B 3280/4885DYRK1A 4694/4885SRC 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.